Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAR-200 and Nivolumab in Muscle-Invasive Bladder Cancer
NCT03518320Phase 1Terminated
- Sponsor
- TARIS Biomedical
- Start
- Jan 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gemcitabine-releasing intravesical system in muscle-invasive bladder cancer (MIBC), sponsored by TARIS Biomedical. Primary endpoints: Incidence of treatment emergent adverse events and Number of participants that do not require treatment discontinuation. Started Jan 2019; status: terminated.
02
Drugs
gemcitabine-releasing intravesical system
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT03518320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03518320.